Literature DB >> 34108780

Optic Nerve Head Blood Flow Analysis in Patients with Optic Disc Drusen Using Laser Speckle Flowgraphy.

Jakob Wågström1, Lasse Malmqvist1, Steffen Hamann1,2.   

Abstract

Visual field defects are common in patients with optic disc drusen (ODD). Our aim was to examine whether reduced optic nerve head (ONH) microcirculation is related to visual field defects in ODD patients. Vascular and tissue area mean blur rate (MBRV and MBRT), measured using laser speckle flowgraphy (LSFG), was significantly lower in the 32 included ODD eyes when compared with 40 healthy eyes (p <.05). There was a moderate correlation between the difference in MBRT and the perimetric mean defect (R2 = 0.53) in ODD patients. These findings demonstrate the utility of LSFG in examining ONH blood flow in ODD patients.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Optic disc drusen; laser speckle flowgraphy; optic nerve head drusen; optic nerve head microcirculation; visual field defects

Year:  2020        PMID: 34108780      PMCID: PMC8158030          DOI: 10.1080/01658107.2020.1795689

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  26 in total

1.  The reduction of temporal optic nerve head microcirculation in autosomal dominant optic atrophy.

Authors:  Maki Inoue; Noriko Himori; Hiroshi Kunikata; Takayuki Takeshita; Naoko Aizawa; Yukihiro Shiga; Kazuko Omodaka; Koji M Nishiguchi; Hidetoshi Takahashi; Toru Nakazawa
Journal:  Acta Ophthalmol       Date:  2016-03-03       Impact factor: 3.761

2.  Ocular microcirculation measurement with laser speckle flowgraphy and optical coherence tomography angiography in glaucoma.

Authors:  Naoki Kiyota; Hiroshi Kunikata; Yukihiro Shiga; Kazuko Omodaka; Toru Nakazawa
Journal:  Acta Ophthalmol       Date:  2018-03-24       Impact factor: 3.761

3.  Anterior and posterior optic nerve head blood flow in nonhuman primate experimental glaucoma model measured by laser speckle imaging technique and microsphere method.

Authors:  Lin Wang; Grant A Cull; Chelsea Piper; Claude F Burgoyne; Brad Fortune
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-17       Impact factor: 4.799

4.  Young Adults with Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study.

Authors:  Steffen Hamann; Lasse Malmqvist; Marianne Wegener; Valérie Biousse; Lulu Bursztyn; Gülsenay Citirak; Fiona Costello; Alison V Crum; Kathleen Digre; Masoud Aghsaei Fard; J Alexander Fraser; Ruth Huna-Baron; Bradley Katz; Mitchell Lawlor; Nancy J Newman; Jason H Peragallo; Axel Petzold; Patrick A Sibony; Prem S Subramanian; Judith Ea Warner; Sui H Wong; Clare L Fraser
Journal:  Am J Ophthalmol       Date:  2020-04-13       Impact factor: 5.258

5.  Pathology and pathogenesis of drusen of the optic nervehead.

Authors:  M O Tso
Journal:  Ophthalmology       Date:  1981-10       Impact factor: 12.079

6.  A clinical analysis of pseudopapilledema. II. Visual field defects.

Authors:  P J Savino; J S Glaser; M A Rosenberg
Journal:  Arch Ophthalmol       Date:  1979-01

7.  Pseudopapilloedema with and without verified optic disc drusen. A clinical analysis II: visual fields.

Authors:  E Mustonen
Journal:  Acta Ophthalmol (Copenh)       Date:  1983-12

8.  Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy.

Authors:  Melinda Y Chang; John L Keltner
Journal:  J Neuroophthalmol       Date:  2019-06       Impact factor: 3.042

9.  Laser speckle flowgraphy derived characteristics of optic nerve head perfusion in normal tension glaucoma and healthy individuals: a Pilot study.

Authors:  Anna Sophie Mursch-Edlmayr; Nikolaus Luft; Dominika Podkowinski; Michael Ring; Leopold Schmetterer; Matthias Bolz
Journal:  Sci Rep       Date:  2018-03-28       Impact factor: 4.379

10.  Prevalence of Optic Disc Drusen in Young Patients With Nonarteritic Anterior Ischemic Optic Neuropathy: A 10-Year Retrospective Study.

Authors:  J Alexander Fraser; Lea L Rueløkke; Lasse Malmqvist; Steffen Hamann
Journal:  J Neuroophthalmol       Date:  2021-06-01       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.